Research ExplorerPublicationsAlphastrahler Radium-223-Dichlorid: Neue Therapie beim kastr...

Alphastrahler Radium-223-Dichlorid: Neue Therapie beim kastrationsresistentes Prostatakarzinom mit symptomatischen Knochenmetastasen

Standard

Alphastrahler Radium-223-Dichlorid: Neue Therapie beim kastrationsresistentes Prostatakarzinom mit symptomatischen Knochenmetastasen. / Heinzer, H; König, F; Klutmann, S.

In: UROLOGE, Vol. 53, No. 4, 01.04.2014, p. 519-523.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Heinzer, H, König, F & Klutmann, S 2014, 'Alphastrahler Radium-223-Dichlorid: Neue Therapie beim kastrationsresistentes Prostatakarzinom mit symptomatischen Knochenmetastasen', UROLOGE, vol. 53, no. 4, pp. 519-523. https://doi.org/10.1007/s00120-014-3436-1

APA

Heinzer, H., König, F., & Klutmann, S. (2014). Alphastrahler Radium-223-Dichlorid: Neue Therapie beim kastrationsresistentes Prostatakarzinom mit symptomatischen Knochenmetastasen. UROLOGE, 53(4), 519-523. https://doi.org/10.1007/s00120-014-3436-1

Vancouver

Heinzer H, König F, Klutmann S. Alphastrahler Radium-223-Dichlorid: Neue Therapie beim kastrationsresistentes Prostatakarzinom mit symptomatischen Knochenmetastasen. UROLOGE. 2014 Apr 1;53(4):519-523. https://doi.org/10.1007/s00120-014-3436-1

Bibtex

@article{5b48015376714f5487c0bb798a9a0ac7,
title = "Alphastrahler Radium-223-Dichlorid: Neue Therapie beim kastrationsresistentes Prostatakarzinom mit symptomatischen Knochenmetastasen",
abstract = "Radium-223 dichloride (Ra-223) is an alpha emitter with low toxicity for the treatment of patients with castrations-resistant prostate cancer (CRPC) and symptomatic bone metastases showing a 30% reduction in the risk of death, as compared to placebo. Because of the favorable physical and chemical characteristics, Ra-223 can be handled easily in daily practice based on interdisciplinary co-operation between urology and nuclear medicine. Ra-223 has been approved under the product name Xofigo{\textregistered} by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).",
keywords = "Alpha Particles, Antineoplastic Agents, Bone Neoplasms, Clinical Trials as Topic, Cooperative Behavior, Dose-Response Relationship, Radiation, Humans, Interdisciplinary Communication, Male, Palliative Care, Prostatic Neoplasms, Castration-Resistant, Radioisotopes, Radium, Survival Rate",
author = "H Heinzer and F K{\"o}nig and S Klutmann",
year = "2014",
month = apr,
day = "1",
doi = "10.1007/s00120-014-3436-1",
language = "Deutsch",
volume = "53",
pages = "519--523",
journal = "UROLOGE",
issn = "0340-2592",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - Alphastrahler Radium-223-Dichlorid: Neue Therapie beim kastrationsresistentes Prostatakarzinom mit symptomatischen Knochenmetastasen

AU - Heinzer, H

AU - König, F

AU - Klutmann, S

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Radium-223 dichloride (Ra-223) is an alpha emitter with low toxicity for the treatment of patients with castrations-resistant prostate cancer (CRPC) and symptomatic bone metastases showing a 30% reduction in the risk of death, as compared to placebo. Because of the favorable physical and chemical characteristics, Ra-223 can be handled easily in daily practice based on interdisciplinary co-operation between urology and nuclear medicine. Ra-223 has been approved under the product name Xofigo® by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

AB - Radium-223 dichloride (Ra-223) is an alpha emitter with low toxicity for the treatment of patients with castrations-resistant prostate cancer (CRPC) and symptomatic bone metastases showing a 30% reduction in the risk of death, as compared to placebo. Because of the favorable physical and chemical characteristics, Ra-223 can be handled easily in daily practice based on interdisciplinary co-operation between urology and nuclear medicine. Ra-223 has been approved under the product name Xofigo® by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

KW - Alpha Particles

KW - Antineoplastic Agents

KW - Bone Neoplasms

KW - Clinical Trials as Topic

KW - Cooperative Behavior

KW - Dose-Response Relationship, Radiation

KW - Humans

KW - Interdisciplinary Communication

KW - Male

KW - Palliative Care

KW - Prostatic Neoplasms, Castration-Resistant

KW - Radioisotopes

KW - Radium

KW - Survival Rate

U2 - 10.1007/s00120-014-3436-1

DO - 10.1007/s00120-014-3436-1

M3 - SCORING: Zeitschriftenaufsatz

C2 - 24604017

VL - 53

SP - 519

EP - 523

JO - UROLOGE

JF - UROLOGE

SN - 0340-2592

IS - 4

ER -